Spyre Therapeutics, Inc.
SYREHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Spyre Therapeutics, Inc. focuses on Biotechnology services and products. Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. Valued at $6.30B, SYRE is a mid-cap name in its sector. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).
Market Cap
$6.30B
Beta
3.13
P/E (TTM)
—
P/E (Fwd)
-24.10
EPS (TTM)
$-2.09
EPS (Fwd)
$-3.01
ROE
-31.1%
ROA
-22.7%
Cash
$741.5M
Total Debt
$0
Free CF
-$75.5M
52W Change
366.3%
Annual Financials
Cash vs Debt
Spyre Therapeutics, Inc. reports $741.5M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$75.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -31.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $2.3M (2022) to $0 (2025), a 100% decline worth watching.
Spyre Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing SYRE's risk profile alongside its fundamentals and technical indicators provides a more complete picture.